CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A

Abstract

Coactivator-associated arginine methyltransferase 1 (CARM1) promotes the development and metastasis of estrogen receptor alpha (ERα)-positive breast cancer. The function of CARM1 in triple-negative breast cancer (TNBC) is still unclear and requires further exploration. Here, we report that CARM1 promotes proliferation, epithelial–mesenchymal transition, and stemness in TNBC. CARM1 is upregulated in multiple cancers and its expression correlates with breast cancer progression. Genome-wide analysis of CARM1 showed that CARM1 is recruited by hypoxia-inducible factor-1 subunit alpha (HIF1A) and occupy the promoters of CDK4, Cyclin D1, β-Catenin, HIF1A, MALAT1, and SIX1 critically involved in cell cycle, HIF-1 signaling pathway, Wnt signaling pathway, VEGF signaling pathway, thereby modulating the proliferation and invasion of TNBC cells. We demonstrated that CARM1 is physically associated with and directly interacts with HIF1A. Moreover, we found that ellagic acid, an inhibitor of CARM1, can suppress the proliferation and invasion of TNBC by directly inhibiting CDK4 expression. Our research has determined the molecular basis of CARM1 carcinogenesis in TNBC and its effective natural inhibitor, which may provide new ideas and drugs for cancer therapy.

Keywords

CARM1 / HIF1A / CDK4 / ellagic acid / TNBC

References

[1] Altun M, Zhao B, Velasco K et al. Ubiquitin-specific protease 19 (USP19) regulates hypoxia-inducible factor 1α (HIF-1α) during hypoxia. J Biol Chem 2012;287:1962–1969.

[2] Amodio N, Raimondi L, Juli G et al. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol 2018;11:63.

[3] Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell 2017;65:8–24.

[4] Burr SP, Costa AS, Grice GL et al. Mitochondrial protein lipoylation and the 2-oxoglutarate dehydrogenase complex controls HIF1α stability in aerobic conditions. Cell Metab 2016;24:740–752.

[5] Ceranski AK, Carreno-Gonzalez MJ, Ehlers AC et al. Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship. Mol Cancer 2023;22:49.

[6] Chen S, Shen X. Long noncoding RNAs: functions and mechanisms in colon cancer. Mol Cancer 2020;19:167.

[7] Chen F, Chen J, Yang L et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol 2019;21:498–510.

[8] Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology. Cell Metab 2018;27:281–298.

[9] Choudhry H, Schodel J, Oikonomopoulos S et al. Extensive regulation of the non-coding transcriptome by hypoxia: role of HIF in releasing paused RNApol2. EMBO Rep 2014;15:70–76.

[10] Choudhry H, Harris AL, McIntyre A. The tumour hypoxia induced non-coding transcriptome. Mol Aspects Med 2016;4:35–53.

[11] Cowman SJ, Koh MY. Revisiting the HIF switch in the tumor and its immune microenvironment. Trends Cancer 2022;8:28–42.

[12] de Heer EC, Jalving M, Harris AL. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest 2020;130:5074–5087.

[13] Dey A, Prabhudesai S, Zhang Y et al. Cystathione β-synthase regulates HIF-1α stability through persulfidation of PHD2. Sci Adv 2020;6:eaaz8534.

[14] Eales KL, Hollinshead KE, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 2016;5:e190.

[15] Fedoriw A, Rajapurkar SR, O’Brien S et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP Loss. Cancer Cell 2019;36:100–114.e25.

[16] Fuhrmann DC, Brüne B. Mitochondrial composition and function under the control of hypoxia. Redox Biol 2017;12:208–215.

[17] Gao JJ, Cheng J, Bloomquist E et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol 2020;21:250–260.

[18] Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 2019;9:176–198.

[19] Genois MM, Gagne JP, Yasuhara T et al. CARM1 regulates replication fork speed and stress response by stimulating PARP1. Mol Cell 2021;81:784–800.e8.

[20] Giamas G, Castellano L, Feng Q et al. CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an estrogen-dependent manner and regulates ERalpha-AIB1 interactions. Nucleic Acids Res 2009;37:3110–3123.

[21] Goolam M, Scialdone A, Graham SJL et al. Heterogeneity in Oct4 and Sox2 targets biases cell fate in 4-cell mouse embryos. Cell 2016;165:61–74.

[22] Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol 2019;20:642–657.

[23] Hosseini ES, Meryet-Figuiere M, Sabzalipoor H et al. Dysregulated expression of long noncoding RNAs in gynecologic cancers. Mol Cancer 2017;16:107.

[24] Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70–78.

[25] Hubbi ME, Gilkes DM, Hu H, Kshitiz, Ahmed I, Semenza GL. Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression. Proc Natl Acad Sci U S A 2014;111:e3325–e3334.

[26] Hupalowska A, Jedrusik A, Zhu M et al. CARM1 and paraspeckles regulate pre-implantation mouse embryo development. Cell 2018;175:1902–1916.e13.

[27] Jarrold J, Davies CC. PRMTs and arginine methylation: cancer’s best-kept secret? Trends Mol Med 2019;25:993–1009.

[28] Kaelin WG. Proline hydroxylation and gene expression. Annu Rev Biochem 2005;74:115–128.

[29] Kalimutho M, Parsons K, Mittal D et al. Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci 2015;36:822–846.

[30] Kim D, Lee J, Cheng D et al. Enzymatic activity is required for the in vivo functions of CARM1. J Biol Chem 2010;285:1147–1152.

[31] Kimura H, Weisz A, Ogura T et al. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 2001;276:2292–2298.

[32] Li S, Cheng D, Zhu B et al. The overexpression of CARM1 promotes human osteosarcoma cell proliferation through the pGSK3β/β-Catenin/cyclinD1 signaling pathway. Int J Biol Sci 2017;13:976–984.

[33] Lorenzen JM, Thum T. Long noncoding RNAs in kidney and cardiovascular diseases. Nat Rev Nephrol 2016;12:360–373.

[34] Madan E, Parker TM, Pelham CJ et al. HIF-transcribed p53 chaperones HIF-1α. Nucleic Acids Res 2019;47:10212–10234.

[35] Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010;40:294–309.

[36] Nair A, Morsy MA, Jacob S. Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. Drug Dev Res 2018;79:373–382.

[37] Nakayama K, Szewczyk MM, Dela Sena C et al. TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget 2018;9:18480–18493.

[38] Peek CB, Levine DC, Cedernaes J et al. Circadian clock interaction with HIF1α mediates oxygenic metabolism and anaerobic glycolysis in skeletal muscle. Cell Metab 2017;25:86–92.

[39] Peng BL, Li WJ, Ding JC et al. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis. Theranostics 2020;10:3451–3473.

[40] Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science 2016;352:175–180.

[41] Salimi A, Roudkenar MH, Sadeghi L et al. Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria. Redox Biol 2015;6:461–471.

[42] Schmid P, Rugo HS, Adams S et al; IMpassioN130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassioN130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:44–59.

[43] Selvi BR, Batta K, Kishore AH et al. Identification of a novel inhibitor of coactivator-associated arginine methyltransferase 1 (CARM1)-mediated methylation of histone H3 Arg-17. J Biol Chem 2010;285:7143–7152.

[44] Semenza GL. Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J 2017;36:252–259.

[45] Shin YC, Joo CH, Gack MU et al. Kaposi’s sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. Cancer Res 2008;68:1751–1759.

[46] Shin HJ, Kim H, Oh S et al. AMPK-SKP2-CARM1 signalling cascade in transcriptional regulation of autophagy. Nature 2016;534:553–557.

[47] Shishkova E, Zeng H, Liu F et al. Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition. Nat Commun 2017;8:15571.

[48] Siegel RL, Miller KD, Wagle NS et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.

[49] Smith KA, Waypa GB, Schumacker PT. Redox signaling during hypoxia in mammalian cells. Redox Biol 2017;13:228–234.

[50] Spring LM, Wander SA, Andre F et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 2020;395:817–827.

[51] Suresh S, Huard S, Dubois T. CARM1/PRMT4: making its mark beyond its function as a transcriptional coactivator. Trends Cell Biol 2021;31:402–417.

[52] Tan AR, Wright GS, Thummala AR et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol 2019;20:1587–1601.

[53] Vadde R, Vemula S, Jinka R et al. Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer. Crit Rev Oncol Hematol 2017;113:22–27.

[54] Wang Y, Zhang H, Chen Y et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009;138:660–672.

[55] Wang N, Wang ZY, Mo SL et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res Treat 2012;134:943–955.

[56] Wang L, Zhao Z, Meyer MB et al. CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis. Cancer Cell 2014;25:21–36.

[57] Wang YP, Zhou W, Wang J et al. Arginine methylation of MDH₁ by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. Mol Cell 2016;64:673–687.

[58] Wang D, Chen Q, Tan Y et al. Ellagic acid inhibits human glioblastoma growth in vitro and in vivo. Oncol Rep 2017a;37:1084–1092.

[59] Wang N, Wang Q, Tang H et al. Direct inhibition of ACTN₄ by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells. J Exp Clin Cancer Res 2017b;36:172.

[60] Wang J, Wang L, Feng G et al. Asymmetric expression of LincGET biases cell fate in two-cell mouse embryos. Cell 2018;175:1887–1901.e18.

[61] Wang Y, Yan S, Liu X et al. PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway. Cell Death Differ 2022;29:1982–1995.

[62] Weng ML, Chen WK, Chen XY et al. Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression. Nat Commun 2020;11:1869.

[63] Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 2006;25:1231–1241.

[64] Zhang HM, Zhao L, Li H et al. Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med 2014;11:92–100.

[65] Zhao M, Tang SN, Marsh JL et al. Ellagic acid inhibits human pancreatic cancer growth in Balb/c nude mice. Cancer Lett 2013;337:210–217.

[66] Zheng K, He Z, Kitazato K et al. Selective autophagy regulates cell cycle in cancer therapy. Theranostics 2019;9:104–125.

[67] Zhong XY, Yuan XM, Xu YY et al. CARM1 Methylates GAPDH to regulate glucose metabolism and is suppressed in liver cancer. Cell Rep 2018;24:3207–3223.

[68] Zhuang Z, Yang C, Lorenzo F et al. Somatic HIF2A gainof-function mutations in paraganglioma with polycythemia. N Engl J Med 2012;367:922–930.

RIGHTS & PERMISSIONS

2024 The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.